Bio-Rad Laboratories (BIO) Stock Rises Good This Week Amid Exiting Q2: Time To Invest Before A Burst Of Profit?

Bio-Rad Laboratories, Inc. (BIO) reached a 52-week high of $783.80 on August 16. Its shares have charted a solid upward trend in recent times. Over the past five years, the company’s earnings growth has accelerated at a fast pace. The stock was trading at $750.08 on August 12, after that the stock started to surge exponentially. As of the last trading session, the stock closed at $770.75, marking a 2.7% increase. Pre-market trading shows no jumps or downs.
Купить Набор контрольных материалов "EQAS, ежемесячная программа по  клинической химии", фасовка 12 х 5 мл Bio-Rad Laboratories, Inc. (США)Bio-Rad is a leading developer and manufacturer of life science and clinical diagnostics. The company’s two business segments, Life Science and Clinical, have been performing well. Bio-Rad Laboratories (BIO – Free Report) second-quarter 2021 results surpassed the expectations of both analysts and investors. The company’s robust top-line growth was supported by the strong performance of its segments. Its robust operating margin expansion is expected to continue in the next couple of years.

Bio-Rad’s robust performance in the second quarter helped boost its segmental sales growth. The company’s Life Science segment, which primarily focuses on biopharma, witnessed robust growth in its sales at CER.

Richard McEntire

Finance and Entertainment ReporterRichard is a bottle of wine - the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.